Connection

LAWRENCE DONEHOWER to Cell Transformation, Neoplastic

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Cell Transformation, Neoplastic.
  1. Enhanced inflammation and attenuated tumor suppressor pathways are associated with oncogene-induced lung tumors in aged mice. Aging Cell. 2018 02; 17(1).
    View in: PubMed
    Score: 0.457
  2. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res. 2012 Jun; 10(6):845-55.
    View in: PubMed
    Score: 0.312
  3. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 2008 Jun; 27(2):123-35.
    View in: PubMed
    Score: 0.238
  4. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 2006 Aug; 45(8):594-604.
    View in: PubMed
    Score: 0.210
  5. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice. Oncogene. 2012 Mar 01; 31(9):1155-65.
    View in: PubMed
    Score: 0.074
  6. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009 Mar 15; 69(6):2559-67.
    View in: PubMed
    Score: 0.063
  7. Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene. Int J Cancer. 2004 Oct 10; 111(6):819-28.
    View in: PubMed
    Score: 0.046
  8. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53.
    View in: PubMed
    Score: 0.038
  9. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.031
  10. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
    View in: PubMed
    Score: 0.027
  11. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 1996 Oct 01; 56(19):4413-23.
    View in: PubMed
    Score: 0.027
  12. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.025
  13. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
    View in: PubMed
    Score: 0.024
  14. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
    View in: PubMed
    Score: 0.018
  15. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011 Nov; 130(2):399-408.
    View in: PubMed
    Score: 0.018
  16. High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine. J Cancer Res Clin Oncol. 2003 Jun; 129(6):335-40.
    View in: PubMed
    Score: 0.010
  17. Sequence comparison in the crossover region of an oncogenic avian retrovirus recombinant and its nononcogenic parent: genetic regions that control growth rate and oncogenic potential. Mol Cell Biol. 1982 Nov; 2(11):1331-8.
    View in: PubMed
    Score: 0.010
  18. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 1995 May 01; 55(9):1963-70.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.